Company intelligence / Profile preview

Vision Medicines

Boston, Massachusetts, United States

Ownership: Private
Employees: ~75
Development stage: Other

Overview

VM200 is a preclinical oral small molecule for Stargardt disease with co-funding through clinical proof-of-concept from Foundation Fighting Blindness. VM100 targets APP for macular dystrophy, also preclinical.

Therapeutic areas: Ophthalmology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

VM200

Preclinical

Partnerships

Foundation Fighting BlindnessCase Western Reserve University

Beyond the preview

Go deeper on Vision Medicines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vision Medicines.

Explore the full profile